Drug | Cost to government (A$) | DDD/1000 pop/day * | Prescriptions |
---|
1. adalimumab | 311 616 305 | 0.57 | 176 062 |
2. rosuvastatin | 206 589 091 | 39.47 | 7 070 240 |
3. aflibercept | 192 839 767 | †
| 123 123 |
4. ranibizumab | 179 612 417 | †
| 116 311 |
5. fluticasone and salmeterol | 175 215 964 | †
| 3 147 115 |
6. esomeprazole | 174 179 985 | 25.27 | 7 170 908 |
7. etanercept | 164 075 133 | 0.31 | 93 629 |
8. rituximab | 156 563 805 | †
| 46 763 |
9. insulin glargine | 142 760 966 | 7.45 | 347 652 |
10. fingolimod | 134 752 870 | 0.19 | 58 858
|
* DDD/thousand population/day is a more useful measure of drug utilisation than prescription counts. It shows how many people in every thousand Australians are taking the standard dose of a drug every day. DDD includes use in combination products. The calcuation is based on ABS 3101.0 – Australian Demographic Statistics for June 2014 (as at December 2014).
† The World Health Organization has not allocated a DDD for this drug.
DDD defined daily dose, PBS Pharmaceutical Benefits Scheme, RPBS Repatriation Pharmaceutical Benefits Scheme
Source: Department of Health, 15 June 2016. © Commonwealth of Australia